United States Biotechnology & Medical Research

Corbus Pharmaceuticals Holdings Inc (CRBP)

Track

Over the past 90 days, Corbus Pharmaceuticals saw mixed insider activity. Chief Business Officer Nishant C. Saxena acquired shares totaling approximately $101,218. Conversely, several executives, including the CEO and CFO, executed planned sales of company stock. These transactions occurred following the company's May 2026 earnings report, amid a 4.9% decline in share price.
Ticker: CRBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Corbus Pharmaceuticals Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Jenkins John Kenneth
2 sales — total 75,972 USD
Planned sale 10 Jun 2026
Value US$4,171,313.73 | Price 451.27 | Shares 71,623
Planned sale 10 Jun 2026
Value US$3,993,957.21 | Price 499.91 | Shares 17,952
Planned sale 10 Jun 2026
Value US$1,127,855.55 | Price 225.73 | Shares 80,287
Planned sale 10 Jun 2026
Value US$3,477,614.24 | Price 476.48 | Shares 58,391
Planned sale 10 Jun 2026
Value US$16,033.16 | Price 7.91 | Shares 2,026
Buy 3 Jun 2026
Value US$68,220.00 | Price 7.58 | Shares 9,000
Buy 2 Jun 2026
Value US$32,998.50 | Price 7.33 | Shares 4,500
Sale 2 Mar 2026
Value US$50,601.44 | Price 8.30 | Shares 6,097
Proposed sale 2 Mar 2026
Value US$50,601.00 | Price 8.30 | Shares 6,097
Sale 17 Feb 2026
Value US$6,253.40 | Price 7.38 | Shares 847
Planned sale 13 Feb 2026
Value US$36,587.88 | Price 7.78 | Shares 4,701
Planned sale 13 Feb 2026
Value US$107,952.44 | Price 7.78 | Shares 13,871
Proposed sale 13 Feb 2026
Value US$812,600.00 | Price 40.63 | Shares 20,000
Sale 3 Feb 2026
Value US$26,574.99 | Price 8.09 | Shares 3,285
Sale 3 Feb 2026
Value US$19,537.11 | Price 8.09 | Shares 2,415
Sale 11 Dec 2025
Value US$344,012.22 | Price 11.46 | Shares 30,029
Planned sale 27 Oct 2025
Value US$153,797.22 | Price 17.14 | Shares 8,973
Planned sale 24 Oct 2025
Value US$317,406.60 | Price 17.01 | Shares 18,660
Proposed sale 24 Oct 2025
Value US$469,977.00 | Price 17.01 | Shares 27,633
Planned sale 24 Oct 2025
Value US$220,936.62 | Price 17.02 | Shares 12,981
Proposed sale 24 Oct 2025
Value US$220,922.00 | Price 17.02 | Shares 12,981
Planned sale 20 Oct 2025
Value US$21,730.00 | Price 20.50 | Shares 1,060
Planned sale 30 May 2025
Value US$20,465.35 | Price 7.35 | Shares 2,783
Planned sale 30 May 2025
Value US$10,095.62 | Price 7.25 | Shares 1,392
Sale 6 Mar 2025
Value US$43,329.84 | Price 6.78 | Shares 6,393
Proposed sale 6 Mar 2025
Value US$43,728.00 | Price 6.84 | Shares 6,393
Planned sale 14 Feb 2025
Value US$24,446.47 | Price 8.76 | Shares 2,792
Proposed sale 14 Feb 2025
Value US$26,468.00 | Price 9.48 | Shares 2,792
Planned sale 14 Feb 2025
Value US$62,464.59 | Price 8.76 | Shares 7,134
Proposed sale 14 Feb 2025
Value US$67,630.00 | Price 9.48 | Shares 7,134
Buy 20 Sep 2024
Value US$572,793.33 | Price 22.23 | Shares 25,769
Buy 20 Sep 2024
Value US$1,021,389.34 | Price 21.47 | Shares 47,564
Buy 20 Sep 2024
Value US$2,849,352.32 | Price 20.42 | Shares 139,551
Buy 20 Sep 2024
Value US$1,296,051.77 | Price 19.61 | Shares 66,088
Buy 20 Sep 2024
Value US$476,313.48 | Price 18.36 | Shares 25,943
Buy 20 Sep 2024
Value US$787,860.38 | Price 17.48 | Shares 45,085
Proposed sale 4 Sep 2024
Value US$50,109.00 | Price 56.43 | Shares 888
Planned sale 18 Jun 2024
Value US$82,479.18 | Price 42.12 | Shares 1,958
Planned sale 18 Jun 2024
Value US$303,219.42 | Price 42.24 | Shares 7,179
Planned sale 18 Jun 2024
Value US$98,074.31 | Price 42.24 | Shares 2,322
Planned sale 18 Jun 2024
Value US$74,759.49 | Price 42.24 | Shares 1,770
Planned sale 18 Jun 2024
Value US$492,779.08 | Price 42.24 | Shares 11,667
Planned sale 17 Jun 2024
Value US$314,789.02 | Price 46.77 | Shares 6,730
Planned sale 17 Jun 2024
Value US$81,455.93 | Price 46.02 | Shares 1,770
Planned sale 17 Jun 2024
Value US$429,507.46 | Price 46.02 | Shares 9,333
Planned sale 14 Jun 2024
Value US$388,417.15 | Price 49.87 | Shares 7,788
Planned sale 14 Jun 2024
Value US$78,152.24 | Price 49.87 | Shares 1,567
Proposed sale 14 Jun 2024
Value US$954,294.00 | Price 52.89 | Shares 18,043
Planned sale 14 Jun 2024
Value US$626,425.34 | Price 50.17 | Shares 12,487
Planned sale 14 Jun 2024
Value US$844,297.15 | Price 50.17 | Shares 16,830
Proposed sale 14 Jun 2024
Value US$3,351,004.00 | Price 52.89 | Shares 63,358
Proposed sale 8 May 2024
Value US$634,876.00 | Price 40.83 | Shares 15,550
Buy 8 Mar 2024
Value US$407,297.52 | Price 45.96 | Shares 8,862
Buy 8 Mar 2024
Value US$7,087,580.22 | Price 45.26 | Shares 156,597
Buy 8 Mar 2024
Value US$2,751,626.16 | Price 44.62 | Shares 61,668
Buy 8 Mar 2024
Value US$802,386.48 | Price 43.26 | Shares 18,548
Buy 8 Mar 2024
Value US$1,055,531.75 | Price 42.25 | Shares 24,983
Buy 8 Mar 2024
Value US$1,209,770.66 | Price 41.23 | Shares 29,342
Buy 7 Mar 2024
Value US$4,211,232.20 | Price 41.23 | Shares 102,140
Buy 7 Mar 2024
Value US$3,612,096.75 | Price 39.99 | Shares 90,325
Buy 7 Mar 2024
Value US$420,099.68 | Price 39.13 | Shares 10,736
Buy 7 Mar 2024
Value US$1,769,938.18 | Price 37.82 | Shares 46,799
Buy 2 Feb 2024
Value US$14,250,000.00 | Price 19.00 | Shares 750,000
Buy 26 Jan 2024
Value US$123,168.00 | Price 38.49 | Shares 3,200
Buy 26 Jan 2024
Value US$1,640,337.46 | Price 37.49 | Shares 43,754
Buy 26 Jan 2024
Value US$602,160.52 | Price 36.53 | Shares 16,484
Buy 26 Jan 2024
Value US$1,157,129.85 | Price 35.83 | Shares 32,295
Buy 26 Jan 2024
Value US$1,092,226.38 | Price 34.62 | Shares 31,549
Buy 26 Jan 2024
Value US$608,634.05 | Price 33.71 | Shares 18,055
Buy 26 Jan 2024
Value US$125,529.02 | Price 32.47 | Shares 3,866
Buy 26 Jan 2024
Value US$131,422.50 | Price 31.86 | Shares 4,125
Buy 26 Jan 2024
Value US$82,274.00 | Price 31.00 | Shares 2,654
Buy 26 Jan 2024
Value US$860,358.48 | Price 29.42 | Shares 29,244
Buy 26 Jan 2024
Value US$894,226.96 | Price 28.82 | Shares 31,028
Buy 26 Jan 2024
Value US$1,017,891.90 | Price 27.70 | Shares 36,747
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-11 2026-06-10 PlS Planned sale
2.1
Jenkins John Kenneth
Non-Executive Director
71,623 -17.0%
451.27
US$4,171,314 		71,623 -17.0% 451.27 US$4,171,314
2026-06-11 2026-06-10 PlS Planned sale
2.1
Jenkins John Kenneth
Non-Executive Director
17,952 +3.7%
499.91
US$3,993,957 		17,952 +3.7% 499.91 US$3,993,957
2026-06-11 2026-06-10 PlS Planned sale
Altmeyer Anne
Non-Executive Director
80,287 +36.9%
225.73
US$1,127,856 		80,287 +36.9% 225.73 US$1,127,856
2026-06-11 2026-06-10 PlS Planned sale
Altmeyer Anne
Non-Executive Director
2,412 -24.1%
7.91
US$19,088 		2,412 -24.1% 7.91 US$19,088
2026-06-11 2026-06-10 PlS Planned sale
Kung Winston
Non-Executive Director
2,026 -14.3%
7.91
US$16,033 		2,026 -14.3% 7.91 US$16,033
2026-06-03 2026-06-03 B Purchase
Saxena Nishant C

Chief Business Officer

Officer
9,000 +13.6%
7.58
US$68,220 		9,000 +13.6% 7.58 US$68,220
2026-06-03 2026-06-02 B Purchase
Saxena Nishant C

Chief Business Officer

Officer
4,500 +7.3%
7.33
US$32,998 		4,500 +7.3% 7.33 US$32,998
2026-03-04 2026-03-02 S Sale
2.9
Smethurst Dominic

Chief Medical Officer

Officer
6,097 -6.4%
8.30
US$50,601 		6,097 -6.4% 8.30 US$50,601
2026-03-02 2026-03-02 PrS Proposed sale
2.9
Smethurst Dominic

Officer

Officer
6,097
8.30
US$50,601 		6,097 8.30 US$50,601
2026-02-18 2026-02-17 S Sale
1.9
Hodgson Ian

Chief Operating Officer

Officer
847 -1.6%
7.38
US$6,253 		847 -1.6% 7.38 US$6,253
2026-02-18 2026-02-13 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
4,701 -4.6%
7.78
US$36,588 		4,701 -4.6% 7.78 US$36,588
2026-02-18 2026-02-13 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
13,871 -7.4%
7.78
US$107,952 		13,871 -7.4% 7.78 US$107,952
2026-02-13 2026-02-13 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
20,000
40.63
US$812,600 		20,000 40.63 US$812,600
2026-02-04 2026-02-03 S Sale
2.9
Smethurst Dominic

Chief Medical Officer

Officer
3,285 -3.3%
8.09
US$26,575 		3,285 -3.3% 8.09 US$26,575
2026-02-04 2026-02-03 S Sale
1.9
Hodgson Ian

Chief Operating Officer

Officer
2,415 -4.4%
8.09
US$19,537 		2,415 -4.4% 8.09 US$19,537
2025-12-15 2025-12-11 S Sale
3.7
Cormorant Asset Management, LP
Large shareholder
30,029 -1.3%
11.46
US$344,012 		30,029 -1.3% 11.46 US$344,012
2025-10-27 2025-10-27 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
8,973 -6.1%
17.14
US$153,797 		8,973 -6.1% 17.14 US$153,797
2025-10-27 2025-10-24 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
18,660 -11.9%
17.01
US$317,407 		18,660 -11.9% 17.01 US$317,407
2025-10-27 2025-10-24 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
12,981 -15.0%
17.02
US$220,937 		12,981 -15.0% 17.02 US$220,937
2025-10-24 2025-10-24 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
27,633
17.01
US$469,977 		27,633 17.01 US$469,977
2025-10-24 2025-10-24 PrS Proposed sale
2.3
Moran Sean F.

Officer

Officer
12,981
17.02
US$220,922 		12,981 17.02 US$220,922
2025-10-21 2025-10-20 PlS Planned sale
Altmeyer Anne
Non-Executive Director
1,060 -14.6%
20.50
US$21,730 		1,060 -14.6% 20.50 US$21,730
2025-06-02 2025-05-30 PlS Planned sale
2.1
Jenkins John Kenneth
Non-Executive Director
2,783 -98.8%
7.35
US$20,465 		2,783 -98.8% 7.35 US$20,465
2025-06-02 2025-05-30 PlS Planned sale
Altmeyer Anne
Non-Executive Director
1,392 -50.0%
7.25
US$10,096 		1,392 -50.0% 7.25 US$10,096
2025-03-07 2025-03-06 S Sale
2.9
Smethurst Dominic

Chief Medical Officer

Officer
6,393 -8.3%
6.78
US$43,330 		6,393 -8.3% 6.78 US$43,330
2025-03-06 2025-03-06 PrS Proposed sale
2.9
Smethurst Dominic

Officer

Officer
6,393
6.84
US$43,728 		6,393 6.84 US$43,728
2025-02-18 2025-02-14 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
2,792 -3.7%
8.76
US$24,446 		2,792 -3.7% 8.76 US$24,446
2025-02-18 2025-02-14 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
7,134 -4.9%
8.76
US$62,465 		7,134 -4.9% 8.76 US$62,465
2025-02-14 2025-02-14 PrS Proposed sale
2.3
Moran Sean F.

Officer

Officer
2,792
9.48
US$26,468 		2,792 9.48 US$26,468
2025-02-14 2025-02-14 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
7,134
9.48
US$67,630 		7,134 9.48 US$67,630
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
25,769 +1.1%
22.23
US$572,793 		25,769 +1.1% 22.23 US$572,793
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
47,564 +2.1%
21.47
US$1,021,389 		47,564 +2.1% 21.47 US$1,021,389
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
139,551 +6.5%
20.42
US$2,849,352 		139,551 +6.5% 20.42 US$2,849,352
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
66,088 +3.2%
19.61
US$1,296,052 		66,088 +3.2% 19.61 US$1,296,052
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
25,943 +1.3%
18.36
US$476,313 		25,943 +1.3% 18.36 US$476,313
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
45,085 +2.2%
17.48
US$787,860 		45,085 +2.2% 17.48 US$787,860
2024-09-04 2024-09-04 PrS Proposed sale
CATLIN AVERY W

Director

Non-Executive Director
888
56.43
US$50,109 		888 56.43 US$50,109
2024-06-18 2024-06-18 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
1,958 -3.9%
42.12
US$82,479 		1,958 -3.9% 42.12 US$82,479
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
7,179 -8.5%
42.24
US$303,219 		7,179 -8.5% 42.24 US$303,219
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
2,322 -2.7%
42.24
US$98,074 		2,322 -2.7% 42.24 US$98,074
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
1,770 -2.1%
42.24
US$74,759 		1,770 -2.1% 42.24 US$74,759
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
11,667 -12.1%
42.24
US$492,779 		11,667 -12.1% 42.24 US$492,779
2024-06-18 2024-06-17 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
6,730 -12.2%
46.77
US$314,789 		6,730 -12.2% 46.77 US$314,789
2024-06-18 2024-06-17 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
1,770 -2.1%
46.02
US$81,456 		1,770 -2.1% 46.02 US$81,456
2024-06-18 2024-06-17 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
9,333 -10.0%
46.02
US$429,507 		9,333 -10.0% 46.02 US$429,507
2024-06-18 2024-06-14 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
7,788 -13.8%
49.87
US$388,417 		7,788 -13.8% 49.87 US$388,417
2024-06-18 2024-06-14 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
1,567 -3.1%
49.87
US$78,152 		1,567 -3.1% 49.87 US$78,152
2024-06-18 2024-06-14 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
12,487 -12.9%
50.17
US$626,425 		12,487 -12.9% 50.17 US$626,425
2024-06-18 2024-06-14 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
16,830 -16.6%
50.17
US$844,297 		16,830 -16.6% 50.17 US$844,297
2024-06-14 2024-06-14 PrS Proposed sale
2.3
Moran Sean F.

Officer

Officer
18,043
52.89
US$954,294 		18,043 52.89 US$954,294
2024-06-14 2024-06-14 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
63,358
52.89
US$3,351,004 		63,358 52.89 US$3,351,004
2024-05-08 2024-05-08 PrS Proposed sale
Brake Rachael Louise

Former Chief Scientific Officer

Officer
15,550
40.83
US$634,876 		15,550 40.83 US$634,876
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
8,862 +0.4%
45.96
US$407,298 		8,862 +0.4% 45.96 US$407,298
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
156,597 +8.4%
45.26
US$7,087,580 		156,597 +8.4% 45.26 US$7,087,580
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
61,668 +3.4%
44.62
US$2,751,626 		61,668 +3.4% 44.62 US$2,751,626
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
18,548 +1.0%
43.26
US$802,386 		18,548 +1.0% 43.26 US$802,386
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
24,983 +1.4%
42.25
US$1,055,532 		24,983 +1.4% 42.25 US$1,055,532
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
29,342 +1.7%
41.23
US$1,209,771 		29,342 +1.7% 41.23 US$1,209,771
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
102,140 +6.3%
41.23
US$4,211,232 		102,140 +6.3% 41.23 US$4,211,232
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
90,325 +5.9%
39.99
US$3,612,097 		90,325 +5.9% 39.99 US$3,612,097
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
10,736 +0.7%
39.13
US$420,100 		10,736 +0.7% 39.13 US$420,100
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
46,799 +3.2%
37.82
US$1,769,938 		46,799 +3.2% 37.82 US$1,769,938
2024-02-06 2024-02-02 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
750,000 +103.4%
19.00
US$14,250,000 		750,000 +103.4% 19.00 US$14,250,000
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
3,200 +0.4%
38.49
US$123,168 		3,200 +0.4% 38.49 US$123,168
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
43,754 +6.5%
37.49
US$1,640,337 		43,754 +6.5% 37.49 US$1,640,337
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
16,484 +2.5%
36.53
US$602,161 		16,484 +2.5% 36.53 US$602,161
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
32,295 +5.1%
35.83
US$1,157,130 		32,295 +5.1% 35.83 US$1,157,130
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
31,549 +5.3%
34.62
US$1,092,226 		31,549 +5.3% 34.62 US$1,092,226
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
18,055 +3.1%
33.71
US$608,634 		18,055 +3.1% 33.71 US$608,634
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
3,866 +0.7%
32.47
US$125,529 		3,866 +0.7% 32.47 US$125,529
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
4,125 +0.7%
31.86
US$131,422 		4,125 +0.7% 31.86 US$131,422
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
2,654 +0.5%
31.00
US$82,274 		2,654 +0.5% 31.00 US$82,274
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
29,244 +5.4%
29.42
US$860,358 		29,244 +5.4% 29.42 US$860,358
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
31,028 +6.1%
28.82
US$894,227 		31,028 +6.1% 28.82 US$894,227
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
36,747 +7.8%
27.70
US$1,017,892 		36,747 +7.8% 27.70 US$1,017,892
Explore more

More insider trading research around Corbus Pharmaceuticals Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America